





Cancer is the 2nd leading cause of death in the United States, and accounts for over 5% of health spending in the U.S. Further, both the disease and financial burden of cancer are predicted to grow in the coming years as the population ages and expensive new treatments are developed. While genomics will play a key role in understanding and treating cancer going forward, recent opinions of cancer treatment also reflect a focus on increasing the efficiency of treatment and strengthening the oncology infrastructure. Meeting these goals will be crucial to the maintenance of Public Health. The Association of American Cancer Institutes (AACI) epitomizes this outlook, and seeks to improve prevention, detection, and treatment of cancer by supporting academic-based cancer centers that receive support from the Nation Cancer Institute (NCI). Their Physician Clinical Leadership Initiative (PCLI) furthers this goal by uniting center leadership and helping them to share vital experience across the nation. As part of this essay, I analyzed data from a self-assessment exercise performed by PCLI at their 2016 annual meeting. Analysis revealed insight into where physician leaders felt their centers were positioned in several key subject areas (such as oncology quality programs, clinical operations, and translating research into practice), where they felt their centers should be, where there was variation in the state of centers across the nation according to physician leadership, and the extent of agreement or disagreement among centers regarding their goals. These results will be used to assess which subject areas are priority targets for improvement. Finally, AACI also reflects the advancing role of genomics in cancer care through their Molecular Diagnostics Initiative. 
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“Cancer” is caused by the presence of so-called malignant cells, which have the ability to multiply uncontrollably, spread to various parts of the body, and invade surrounding tissues. Cancer morbidity and mortality are one of the leading health challenges in the United States. Across all cancer sites (such a breast, colorectal, and lung), the 2009-2013 U.S. cancer incidence rate was 446.5 per 100,000 persons1. According to the 2016 National Vital Statistics Report, malignant neoplasms (i.e. cancer) were the 2nd highest cause of death in the United States in 2014, with 22.5 percent of total deaths, second only to diseases of the heart. In total, cancer accounted for 591,699 reported deaths in 20142. These rates reflect the inherent difficulty of effectively treating cancer. Tumors often develop multidrug resistance if patients survive initial treatment with chemotherapy, making long-term survival difficult even if remission is achieved. Surgical methods are usually only effective if the tumor is identified in an early stage and has not yet metastasized, and still often require follow-up with chemical or biological agents to ensure the entire tumor is destroyed3. Cancer patients are therefore often both difficult and very expensive to treat. The National Institutes of Health (NIH) estimates that $89 billion were spent on cancer care in 2007, and that the total economic burden after accounting for lost productivity and death was approximately $219.2 billion. In total, cancer alone accounts for approximately 5% of United States healthcare spending4.  
Fortunately, advancements in early detection and treatment are being made. As a society develops, cancers and other chronic illnesses become prominent and overtake infectious diseases as the primary threat to population wellbeing. As subjects/people in developed societies continue to lead longer, healthier lives, inborn and chronic diseases take up a more and more significant proportion of the disease burden. Part of this increase is due to societal trends such as rising obesity rates, but largely it simply results from these diseases, which tend to accrue over time, being given the opportunity to manifest5. This trend has been and is being met with an increased interest by health officials in combating chronic diseases and cancer. Since the 1990s, the overall cancer death rate for adults in the U.S. has generally declined. From 2003 to 2012, death rates declined by an average of 1.5% per year. During this time, cancer incidence rates also fell by an average of 0.7% per year, despite an aging population and increased disease detection6. This fall in incidence rates across the nation can be partially attributed to a decline in tobacco smoking rates thanks to public health tobacco-control efforts7. Improvements in cancer death rates and 5-year survival rates results from new agents that improve outcomes for cancer patients, as well as new technologic advances in screening, robotics, and therapeutic radiology. However, these new treatments are expensive, and often fail to meet measures of cost effectiveness, such as dollars per quality-adjusted life years (QALY), when compared to existing treatments8,9,10. In addition to the financial burden on society, these high costs are a significant burden on patients and their families as well; a nationally representative survey in 2006 of 930 U.S. adults aged 18 and older who either were cancer patients or had a family member in their household who was a patient showed that even among individuals with insurance, 25% reported using up most or all of their savings paying for their cancer treatment and 33% of families reported problems paying their cancer treatment bills4. Even when only taking population growth into account, the cost of cancer care is predicted to increase. In 2011, it was predicted to increase from $124.57 billion in 2010 to $157.77 in 2020. By including a 2% annual increase in cost of care, such as might be seen from the development of expensive new treatments, that prediction rises to $173 billion11. 
In response to the growing health and economic burden of cancer and cancer care, current developments in the healthcare sector related to cancer care can be broadly divided into three areas. Firstly, the development of advanced new treatments continues. For example, in 2016 Stracquadanio, G. et al. demonstrated that commonly inherited genetic variants in the p53 stress response pathway affect the incidence of a broad range of cancers in a similar way to previously studied p53 somatic mutations, providing new insight into cancer screening and treatment options12.  As a further example of what has been done just since 2016, Armand, P. et al. demonstrated a favorable safety profile and response in patients with hematologic malignancies for a new treatment targeting a common genetic vulnerability of Classical Hodgkin lymphoma13. Theoretically, by giving only the most effective agents to a particular patient and streamlining the discovery process of what treatment will be most effective, the cost-effectiveness of new agents can be improved and the overall cost to patients reduced. This is the theory behind personalized medicine, and a key component of achieving personalized medicine is a broad array of treatment agents and a thorough understanding of the mechanisms behind those agents. Secondly, health care practitioners continue to improve the support systems for treatment delivery. Meropol, N.J., et al., in the American Society of Clinical Oncology Guidance Statement: The Cost of Cancer Care, recognized the need for further research in areas such as physician-patient communication, medical decision making, and defining value in cancer care in order to improve population well-being and patient outcomes4, and similar outlooks are gaining traction across the healthcare sector. Thirdly, the healthcare sector is starting to emphasize preventative measures as a key component of addressing the burden of cancer. Healthy People 2020 lists obesity and unhealthy behaviors, such as smoking and lack of physical activity, as an emerging issue in cancer development, and the 2016 Annual Report to the Nation on the Status of Cancer focuses on preventive measures, such as screening, as the key to combating the rising disease burden of liver cancers6,14. Finally, some health care practitioners recognize that as cancer treatments become more diverse and complicated, simple measures of clinical outcomes such as death rates and direct costs will not fully represent the value of a given treatment or treatment strategy. In 2006, Reeder and Gordon discussed how to best manage cancer costs and described several models for assessing the value of an oncological treatment. These assessments include a combination of traditional outcomes research to determine the effectiveness of a treatment, pharmacoeconomic approaches to assess efficiency and costs vs. consequences, consideration of a variety of perspectives on the value of a treatment, and also incorporating humanistic costs and consequences, such as patient satisfaction with a treatment15. As preventative efforts continue to become a key part of complete cancer care and creation of an efficient, unified standard of optimal care becomes more complex, the unification of the healthcare industry and the public health practices will be necessary. 
1.1	ThE Association of American Cancer Institutes
The Association of American Cancer Institutes (AACI, http://www.aaci-cancer.org/ (​http:​/​​/​www.aaci-cancer.org​/​​)) membership includes 96 National Cancer Institute (NCI)-designated centers (https://www.cancer.gov/research/nci-role/cancer-centers (​https:​/​​/​www.cancer.gov​/​research​/​nci-role​/​cancer-centers​)) and academic cancer research centers that receive NCI support. In addition to performing research to better understand cancer biology and discover new cancer treatment methods, these centers provide the communities they are located in with access to cancer experts that can provide prevention, diagnosis, treatment, and patient care services. The goal of the AACI is to reduce the burden of cancer by coordinating and supporting the efforts of academic cancer centers. It also works closely with the NCI, NIH, other like-minded organizations, and with corporate partners by forming coalitions and connecting their member centers with these organizations16. In addition to these core functions, AACI also continually seeks to improve and expand what it can achieve for its member centers through several initiatives in key areas of interest. 
The AACI’s Academic Difference Initiative seeks to document the value that academic cancer centers provide by bridging the gap between cutting edge advancements and general oncology care. Because cancer and cancer care are redefined at a rapid rate by new advancements, the ability of these academic centers to integrate these advancements rapidly into actual care is critical.  The Academic Difference Initiative intends to facilitate this integration and assess its progress in a quantitative way. The Network Care Initiative aims to meet one of objectives of the 2016 “Cancer Moonshot” by facilitating cooperation between the AACI academic cancer centers and community points of cancer care. The Cancer Moonshot, funded with $1.8 billion over 7 years by the 21st Century Cures Act in 2016, aims to accelerate cancer research and improve our ability to prevent and treat cancer (https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative (​https:​/​​/​www.cancer.gov​/​research​/​key-initiatives​/​moonshot-cancer-initiative​)). By increasing the availability of experts, advanced technologies, and clinical trials to patients seen by community care centers, AACI will facilitate achievement of this second objective. AACI also aims to meet the ever-growing need for new and improved cancer clinical trials through their Clinical Research Initiative. The CRI both develops best practices for the operation of cancer center clinical research facilities and leverages the collective influence of the AACI’s member cancer centers to advocate for national improvements in the arena of clinical trials. As cancer care moves away from a focus on anatomical site diagnostics and towards molecular tumor characteristics17, another initiative, the Molecular Diagnostics Initiative, seeks to overcome the barriers to implementation of molecular diagnosing and treatment in cancer centers. These barriers include acquiring appropriate tissues, developing mutation panels to test against, selecting technological platforms, and overcoming reimbursement challenges. The Oncology Workforce Initiative seeks to address a looming deficiency of oncology care providers as the number of Americans age 65 and older continues to grow. As part of this initiative, AACI has been involved in several partnerships with other organizations to improve the recruitment, training, and retention of the oncology workforce. The Physician Clinical Leadership Initiative (PCLI) is a forum for physician leaders to share “best practices” that will enable cancer centers to address the many challenges they face in the modern world, such as rising costs of treatment, delivering best care, and staying abreast of the latest advancements. PCLI provides a place where physician leaders can build consensus and share experience regarding these issues. Finally, Project Cancer Education is aimed at state and federal legislators, to help them understand the complex process of translating medical research into new cancer treatments. By bringing participants into a cancer center, this initiative will promote awareness of the importance of academic cancer centers and the challenges inherent in maintaining them at the legislative level. 
1.2	Statement of Intent
The goals and activities of AACI are indicative of the direction healthcare and public health practices are headed in the upcoming decades. As can be seen in the recent goals of many U.S. health departments and in programs like Healthy People 2020, there is a growing focus on delivering healthcare efficiently as well as effectively, and on understanding how to best utilize available resources. AACI is bringing this new focus to one of the most challenging areas of healthcare. Within their programs, PCLI particularly seeks to empower AACI cancer centers to meet the challenges of recent expectations of medical care by uniting the cancer center leadership in practice and in intent. As American expectations of healthcare continue to rise, creating a quality standard of care comprised of “best practices” across the nation will be key, and unifying the efforts and experiences of these centers will also help them to swiftly produce new advances and robustly incorporate these advances into standard care. With an aging population and cancer already the second leading cause of death in the nation, these issues will only become more pressing. After a brief look at the activities of the PCLI, the following sections will explore data from a recent exercise that sought to determine the current and target states of AACI cancer centers in several key areas. 
Human genetics also has a growing role in cancer treatment, both in the development of new targeted therapies and in better understanding tumor physiology, potentially improving diagnostic and treatment efficiency. Like many organizations, AACI is interested in removing the barriers to implementation of genomic strategies in cancer treatment and detection; subsequent sections of this essay will briefly explore and justify the direction and implementation of current research results. 
2.0 	The Physician Clinical Leadership initiative (PCLI)
The PCLI is led by a steering committee, comprised and chaired by physician leaders from AACI member cancer centers. The committee performs the leadership and managerial functions necessary for the PCLI to operate and monitors metrics to ensure PCLI continues to be effective. The full body of PCLI participants, also physician leaders from the various centers, meets annually to collaborate and discuss challenges. As part of the meeting of PCLI at the 2016 AACI annual meeting, attendees were asked to participate in a self-assessment exercise of five key subject areas for their centers, measured across one or more metrics, for a total of seven subject area metrics. The subject areas (and metrics) measured included: 
1. Oncology Quality Program




Clinical Operations refers to the internal mechanisms and day-to-day functioning of the clinical care delivery component of AACI cancer centers. This is a key subject area both for improving value-to-cost ratios by improving efficiency and for ensuring that patients and providers are in a good environment for ensuring delivery of quality multidisciplinary care. Clinical Operations at participating centers (as perceived by physician leadership) was measured on the metrics of chaotic to efficient (3), and physician-centric to patient-focused (4). 
3. Network Site Incorporation
	Network Site Incorporation represents the progress of AACI academic cancer centers in connecting with community cancer care facilities in their area, which are often independent of large cancer centers and may lack some of the most up-to-date treatments and resources. This subject area aligns with the Network Care Initiative, a larger effort to ensure broad patient access to state of the art care through community center partnerships. Network Site Incorporation at participating centers (as perceived by physician leadership) was measured on the metric of rudimentary to established (5). 
4. Research into Practice
	This subject area focuses on how swiftly and robustly new advancements in clinical cancer research are incorporated into clinical cancer care, especially at academic cancer centers. It aligns with the goal of the AACI’s Clinical Research Initiative to develop best practices related to effectively maintaining a research cancer center. Research into Practice at participating centers (as perceived by physician leadership) was measured on the metric of challenging to harmonious (6). 

5. Reimbursement and Incentive Programs (for Clinical Care and Research)
This subject area reflects the effective presence of programs meant to reimburse physicians for time spent participating in clinical research activities, and to incentivize them to do so. It is a critical area given the many barriers of complexity, regulatory difficulty, and more that can exacerbate the time commitment required to become involved with clinical trials for physicians and their patients. Reimbursement and Incentive Programs at participating centers (as perceived by physician leadership) was measured on the metric of absent to present and effective (7).
For the self-assessment exercise, each subject area was represented by a poster that contained one or two scales, one for each metric measured, which ranged from one extreme state to another. Each scale was 68cm long, with one extreme state (e.g., undeveloped) leftmost at 0cm and one extreme state (e.g., comprehensive) rightmost at 68cm. Participants anonymously placed a red sticker on the scale to indicate the current state of their center and a green sticker to represent where they wanted center to be in the future. The location of each sticker was measured in cm to determine each participant’s perception of their center’s current and target state in that metric relative to the specific subject area. Although these data only represent the perceptions of the physician leaders involved, they provide a useful measure of where consensus about key subject area goals is lacking across AACI member centers, and a proxy measure of how well these centers are currently achieving their respective goals. Using these data, AACI was interested in assessing, for each subject area metric: 1, Where on the spectrum the centers currently reside; 2, Where on the spectrum physician leadership think their center should be, and where this is relative to perceptions of current state; 3, Whether levels of variation in perception of current state are high or low, and if high, if this could be used to take lessons from centers perceived to be performing well; and 4, Levels of variation in perception of target state (i.e., agreement between centers about what the goals of AACI centers should be). 
To assess these questions, using Microsoft Excel the means and variances of current and target states for each subject area metric were calculated.  Potential differences between current states and target states, or current states and the perceived midline of the scale (the point perceived to be halfway between the leftmost and rightmost states) were evaluated using two-tailed t-tests (with unequal variances) at the 95% confidence level.  
2.1	Overall Results
The physician leadership of 44/96 (46%) AACI member cancer centers were present at the meeting.  Of these physician leaders, 29 to 36 (66% to 82% of attendees) participated in the assessment activity for each subject area metric.  
All physician leaders wanted to move their cancer centers further (i.e. rightward) on the scale for each subject area (Figures 1 and 2). In other words, the mean perceived target state of centers was significantly higher than the mean perceived current state for all subject area metrics (p < 4x10-11 for each metric, Table 1). The internal distance between mean current state and mean target state for each metric ranged from 22.9 to 38.3 cm (Figure 3). By comparison, the mean perceived current state of centers for most metrics was similar to the perceived midline of the scales. With the exception of two subject areas, the differences between the means and the midline was non-significant (Table 1). Of the two that were significantly different, the subject area of Oncology Quality Program (ranged from leadership-driven to stakeholder-driven) was perceived to be currently significantly driven more by leadership than by stakeholders (17.2 ± 1.5cm, p = 9.2x10-10). Similarly, the subject area of Reimbursement and Incentive Programs (ranged from absent to effective) was perceived to be currently significantly more absent than present and effective (20.5 ± 2.5cm, p = 9.4x10-5). This suggests that the current state of AACI centers is perceived to be significantly removed from any “middle ground” in these metrics, not only from the perceived target state. Although the subject area of Research into Practice (ranged from challenging to harmonious) was not significantly different from the perceived midline, participants did perceive their centers to be closer to challenging than harmonious on the scale (27.2 ± 2.5cm, p = 0.08).   
In addition to differences across subject area metrics, there is also variability within the measures of the perceived current and target states of each metric (Figures 1 and 2). For example, the variation within perceptions of current state within subject area metrics ranged from a standard deviation of 8.5cm (13% of the 68cm scale) for Oncology Quality Program (ranged from leadership-driven to stakeholder-driven) a value almost twice as large, 17.5cm (26% of the 68cm scale) for Network Site Incorporation (ranged from rudimentary to established) (Table 1). In comparison, the standard deviations for perceptions of target state ranged from 3.7cm (5% of the 68cm scale) for Clinical Operations (ranged from chaotic to efficient), to 11.1cm (16% of the 68cm scale) for Oncology Quality Program (ranged from leadership-driven to stakeholder-driven) and Clinical Operations (ranged from physician-centric to patient-focuses), a three-fold difference (Table 1). 


Figure 1. Perceptions of Current State





Figure 2. Perceptions of Target State





Figure 3. Distance Between Current and Target States
Distance on the scale of each metric between the mean perceived current state of each center and the mean perceived target state.

Table 1. Comparisons of Means and S.D. of Perceived Current State and Target State for Seven Subject Area Metrics
Categories	Current State (cm)	Current to midlinep-value	Target State (cm)	Difference, Target – Current (cm)	Difference p-value
Oncology Quality Program:      Undeveloped to Comprehensive	32.4 ± 11.9	0.62	58.4 ± 5.5	26.1	2.3E-15
Oncology Quality Program:      Leadership-Driven to Stakeholder-     Driven	17.2 ± 8.5	9.2E-10	48.3 ± 11.1	31.1	5.0E-17
Clinical Operations:     Chaotic to Efficient	32.9 ± 11.6	0.42	59.8 ± 5.0	26.9	5.0E-17
Clinical Operations:     Physician-Centric to Patient-Focused	29.4 ± 14.3	0.42	52.2± 11.1	22.9	4.0E-11
Network Site Incorporation:     Rudimentary to Established	30.3 ± 17.5	0.73	59.4 ± 6.2	29.1	3.9E-11
Research to Practice:     Challenging to Harmonious	27.2 ± 14.0	0.08	61.8 ± 3.7	34.6	6.4E-17
Reimbursement & Incentive Programs:     Absent to Effective	20.5 ± 14.0	9.4E-05	58.8 ± 8.0	38.3	1.2E-18


These results indicate that the perceived current status of AACI cancer centers varies substantially within each subject area, but this variation is similar across subject areas.  This scenario is not surprising if the difference centers perceive themselves at different starting points.  In contrast, most centers want to reach a similar target state, that is the standard deviations overall areas are lower.  However, because the magnitude of variability within subject areas differs more among target states, there may be significantly more disagreement over the desirable target state of some subject area metrics than there is in others. These data provide a proxy measure for where AACI cancer centers are the most inconsistent across these subject areas, and show where consensus-building may be required to create shared goals across the AACI. The following sections provide a closer analysis of the data as it pertains to each individual metric used for the surveyed subject areas. 
2.2	oncology quality Program
2.2.1	Undeveloped to Comprehensive
Across all measures, the results of each center’s assessment of Oncology Quality Program (ranged from undeveloped to comprehensive) were somewhat moderate. The mean perceived current state of cancer centers was 32.28±11.85cm, and the mean perceived target state was 58.43±5.47cm. The mean perceived current state is not statistically significantly different from the perceived midline. While there is a high objective level of variance within the perception of current state (Table 1 and Figure 1), relative to other subject area metrics perceptions of the current state of Oncology Quality Program as undeveloped to comprehensive for AACI member clinics are only moderately variable. There is significantly more agreement about what the target state should be for this subject area metric, but it remains a moderate measure relative to other subject area metrics (Table 1 and Figure 2). The current perceived state’s lowest data point is 11.7cm, and its highest is 52.4cm. This subject area metric has the sixth largest distance between its mean perceptions of current and target state, at 26.05cm (Figure 3). As a result, relative to other measures Oncology Quality Program (ranged from undeveloped to comprehensive) would benefit from continued effort, but may not be a priority relative to other key areas of potential improvement. 
2.2.2	Leadership-Driven to Stakeholder-Driven
Across all measures, Oncology Quality Program (ranged from leadership-driven to stakeholder-driven) appears to be a contentious subject area metric. It has the lowest (i.e. most leftward) mean perception of current state across metrics at 17.22±8.45cm, and its mean perceived current state is also statistically significantly smaller than the midline, with the greatest distance from the midline (Table 1).  However, this metric also has the lowest mean perception of target state across metrics at 48.34±11.14cm.  Further, while there is the most agreement among all metrics over the perceptions of current cancer center state for this subject area metric (Table 1 and Figure 1), it is one of two subject area metrics with the most variance among perceptions of target cancer center state (Table 1 and Figure 2).  The current state’s lowest data point is 2.5cm, and its highest is 37.6cm. This subject area metric has the third largest distance between its mean perceptions of current and target state, at 31.12cm (Figure 3). In summary, physician leadership at AACI centers have drastic and definitive perceptions of where Oncology Quality Programs as leadership-driven to stakeholder-driven currently lie, and there is a large gap between this state and the desired target state. However, the mean perception of target state is a drastic departure from most subject area metrics themselves, and suffers from a significant lack of agreement as shown by the high variance. These results suggest that this subject area metric requires action, but more importantly, indicate that consensus-building needs to occur prior to planning for action.
2.3	Clinical Operations
2.3.1	Chaotic to Efficient
Across all measures, Clinical Operations (ranged from chaotic to efficient) are a relatively positive metric. The metric has the highest mean perception of current state at 32.93±11.61cm, though it is not statistically significantly different from the midline (Table 1). Although the variability across centers regarding the current state is high, it is among the less variable metrics (Table 1 and Figure 1). This subject area metric is also among the least variable metrics in perceptions of target state (Table 1 and Figure 2). This low variability centers around a relatively high mean perception of target state of 59.83±5.02cm, which explains why this subject area still has the fifth largest distance between current and target states at 26.91cm despite its high mean perceived current state (Figure 3). The current state’s lowest data point is 10.0cm, and its highest is 53.6cm. Perceptions of Clinical Operations in cancer centers (ranged from chaotic to efficient) already lean strongly towards the rightmost state (efficient), although no statistically significantly more so than the other subject areas. However, there is a strong consensus for improvement; this strength and consistency of agreement may make it possible and desirable to develop best practices from the clinics perceived to be doing the well and apply them to centers perceived to be lagging.
2.3.2	Physician-Centric to Patient-Focused
Across all measures, Clinical Operations (ranged from physician-centric to patient-focused) were highly variable. This subject area metric has a moderate mean perception of current state at 29.36±14.33cm, but it has the second lowest mean perception of target state at 52.22±11.12cm. This observation results in the smallest distance between mean perceived current and target states across all subject area metrics, at 22.86cm (Figure 3). Perceptions of the current state of this subject area metric are also highly variable, among the largest standard deviations of mean perceived current states (Table 1 and Figure 1). Significantly, the low mean perceived target state of this subject area metric has one of the two highest standard deviations of mean perceived target states (Table 1). The current state’s lowest data point is a very low 1.5cm, while its highest is 60.3cm. The combination of high current state variability, high target state variability, and low distance between mean current and target states suggests that Clinical Operations (ranged from physician-centric to patient-focused) should undergo investigation and consensus-building before any action is taken to move AACI cancer centers towards a particular model of operation. 
2.4	Network Site incorporation
2.4.1	Rudimentary to Established
Across all measures, Network Site Incorporation (ranged from rudimentary to established) was inconsistent. Its mean perception of current state is not statistically significantly different from the midline, at 30.31±17.50cm (Table 1). The distance between the mean current and target states is the fourth largest of the seven subject area metrics, at 29.05cm (Figure 3). This subject area metric additionally has the highest level of variance of perceptions of current state across cancer centers among all subject area metrics (Table 1 and Figure 1). However, it has only a moderate level of variance within perceptions of target state (Table 1 and Figure 2). The current state’s lowest data point is 5.8cm, and its highest is the largest among current state data points at 65.6cm. Taken all together, Network Site Incorporation (ranged from rudimentary to established) is average across the entire surveyed AACI member center body relative to other key subject area metrics, but varies widely among individual centers. This variability may be due to different needs, as well as the availability and needs of network sites based on geography. This observation indicates that this subject area would benefit from a needs assessment of member centers and their community care peers. Next, centers perceived to be doing exceptionally well could relate experiences to lagging centers with profiles that match well, thus improving consistency and overall success within this metric. However, other subject areas might require first priority across AACI.
2.5	Research into Practice
2.5.1	Challenging to Harmonious
Across all measures, Research into Practice (ranged from challenging to harmonious) presents itself as a good target for future action. Its mean perception of current state, at 27.16±14.01cm, is not statistically significantly different from the midline, but it is the third lowest mean of that measure across subject area metrics (Table 1). By comparison, its mean perception of target state is the highest mean of that measure (Table 1). Thus, it has the 2nd largest distance between mean perceived current and future states at 34.60cm (Figure 3). Furthermore, although perceptions of current state in this subject area metric vary widely (Table 1 and Figure 1), it shows the most agreement among perceptions of target state (Table 1 and Figure 2). The current state’s lowest data point is 3.3cm, while its highest is 51.0cm. Therefore, center leadership perceives a need to improve both strength and consistency of Research into Practice (ranged from challenging to harmonious) across AACI cancer centers, and display a strong and consistent desire to improve. Given that no individual centers perceive themselves to be performing exceptionally well relative to high perceptions present in other subject area metrics, this metric presents itself as a good candidate for a policy-level intervention or structural program. 
2.6	Reimbursement and Incentive Programs
2.6.1	Absent to Effective
Across all measures, Reimbursement and Incentive Programs (ranged from absent to effective) were a key subject area metric of concern. This metric’s mean perception of current state is among two that are statistically significantly different from the midline (Table 1). It also has a high mean perception of current state at 58.75±7.98cm. As a result, this metric’s distance between mean current and target states is the largest, at 38.25cm (Figure 3). Further, both its perceptions of current and target states among physician leadership have high levels of variability (Table 1 and Figures 1 and 2).  This subject area metric also has the smallest low current data point at 1.4 cm, and its highest current data point is only 45.0cm. These results indicate a high level of concern among participants regarding the current state of this subject area metric in their cancer centers, as well as a variable but high level of desire for improvement. The apparent need for improvement suggests that Reimbursement and Incentive Programs (ranged from absent to effective) requires an assessment to accurately define the issue. Depending on the results of that assessment, decisive action may be required to close the gap between current and target states of this metric in AACI academic cancer centers. 
3.0 	The Role of Human Genetics
In recent years, human genetics research has helped redefine the future of cancer care. Uncovering mutation and expression profiles has helped to classify tumors into several subtypes based on their molecular characteristics18. This process is still ongoing today; for example, in March of 2016 Bailey, P. et al used genomic analysis to identify 32 recurrently mutated genes that defined 4 molecular subtypes of pancreatic tumors, including squamous, pancreatic progenitor, immunogenic, and ADEX tumors19 The Cancer Genome Atlas at the NIH has also greatly facilitated increased awareness about the molecular characteristics of cancerous tumors (https://cancergenome.nih.gov/ (​https:​/​​/​cancergenome.nih.gov​/​​)). These results have also led to a growing consensus that, though the unique environment of an individual tumor will remain critical to treatment, most tumors arise from the deregulation of a group of core signaling pathways, promoting a tumor mutation-centric rather than tumor location-centric approach to care17,20,21. This assumption has three direct consequences for future diagnosis and treatment modalities. 
One, as human genetic and biochemical research continues to identify which mutations and biological molecules are characteristic of various cancers, these findings will provide candidate biomarkers for use in cancer screening and diagnosis. For example, microRNAs, small non-coding RNA segments, have become well recognized regulatory molecules in human biology over the past two decades, and have been the subject of several studies linking them to cancers22. Circulating tumor DNA (ctDNA) is also well accepted as having many useful potential applications for cancer diagnosis and management23. More recently, in March of 2015, Iyer, M.K. et al created a foundational database of long noncoding RNAs (lncRNA) in the human transcriptome, and demonstrated a relationship between several of these lncRNAs and various cancer types24. By cataloguing which molecules (in their case, lncRNAs) are selectively expressed or absent in certain tumor types, researchers may design tests to detect the presence or absence of these molecules. High quality tests of this nature will help health practitioners to quickly identify cancer cases and discover detailed information about the nature of the tumor(s) involved. 
Two, understanding the molecular makeup of tumors (such as proteins and noncoding RNAs present) by extension of their genetic makeup will enable physicians to target medications. Identifying which specific pathways are abnormal, and how, in a given tumor, along with thorough understanding of our medications, will allow health practitioners to select a treatment agent that is the most effective for a given patient. As stated before, this is the core philosophy behind personalized/precision medicine in cancer care. Several studies have already demonstrated this differential response of different tumor subtypes to different forms of treatment25, 26, 27. This will not only provide better outcomes for the patient, but will increase the cost-effectiveness of these expensive medications. As more advanced treatment agents continue to be developed and cost-effective cancer care simultaneously becomes an increasing concern, ensuring the efficiency of our treatments by using targeted therapies will be a key aspect of providing quality cancer care. 
Three, we will continue to make advances in the development of better cancer treatment agents, enabled by understanding the genetic makeup and biochemical consequences of cancerous tumors. The benefits of current cancer treatments may be uncertain, especially when considering cost and patient suffering; developing more effective treatments will help to alleviate this concern28. Some of the most recent advancements in this area were described previously, and research of this nature will continue12,13. Although many new developments are typically costly, difficult to implement in a clinical setting, and initially of uncertain benefit, continued research and innovation is required to develop treatment regimens that do work, and that will ultimately “cure” cancer4,9. A thorough understanding of the mechanisms by which tumors develop and maintain themselves will be key to achieving this goal. 
3.1	AACI: Molecular Diagnostics 
The contributions of genetic and biochemical research cannot bring value to cancer treatment if they are not supported by the health infrastructure and adopted by cancer care providers. AACI’s Molecular Diagnostics Initiative (MDI) recognizes the need to adapt these advanced practices for cancer care within healthcare and public health. In AACI’s Spring 2013 Commentary, the president of AACI wrote: 
“Historically, the clinical management of patients with cancer has been based on the anatomic site and tumor histology. In the past few decades, the identification of pathogenic mutations within oncogenes or tumor suppressor genes that confer sensitivity to targeted therapies has resulted in a paradigm shift to one where the molecular characteristics of a tumor play a critical role in guiding the selection of therapy16.”
The primary role of MDI is to facilitate this shift by helping academic cancer centers to overcome barriers faced by biochemical and genetic advancements attempting to enter the treatment landscape, specifically in the case of using molecular biomarkers for cancer diagnosis. Like PCLI, MDI has a steering committee that oversees the initiative, establishes goals and metrics, sets agendas, and identifies participants, in addition to other key tasks.  Chief among MDI’s activities, the Test Panel working group is charged with developing a government-approved, standardized test panel of genes and mutations for testing cancer tissues. This task is potentially quite challenging, as such a panel must cover all major tumor types with high sensitivity and specificity. However, success would provide a national, compelling foundation for building molecular diagnostic programs and tissue collection capabilities. The lack of such programs is currently a severe infrastructure barrier to implementation of molecular diagnosis. MDI was part of the AACI’s 2013 presidential initiative, and though it faces several challenges to completing its goals, the initiative represents a necessary push towards a new model of cancer care. 
4.0 	ConcluSions
The efforts of the AACI reflect the overall direction in which cancer care is headed. While continuing to support the discovery of new treatments, they are also turning their attention towards creating a standard of care and improving the efficiency with which cancer care is delivered. Especially as healthcare moves towards a pay-for-performance mindset and state-of-the-art cancer care becomes more costly, this will become an increasingly pressing concern. Addressing the disease burden of cancer is key not only for the healthcare sector, but also for public health, as cancer and other chronic diseases comprise and increasing percentage of the mortality within the United States and other developed nations. AACI attempts to accomplish this partially by being a unifying and experience-sharing force for academic cancer centers. Even within AACI, PCLI is an effort to unify center physician leadership around developed best practices, and to provide support in several key subject areas as the cancer care sector continues to advance. Based on the survey poster exercise from the 2016 meeting of PCLI at the 2016 AACI/CCAF Annual Meeting, a few subject areas stand out as particular candidates for focused attention. 
Three metrics out of seven were perceived to be most pressing. Research into Practice (ranged from challenging to harmonious) stood out as the most likely priority. It had both a large perception of needed improvement and widespread agreement on the level of improvement needed, as well as a need to increase the consistency of the current state of this metric across AACI centers (as perceived by physician leadership). Additionally, as bringing research into practice effectively is a unique benefit of the academic cancer centers that make up the AACI, this is a clear target area that both requires improvement and presents itself as a good candidate for improvement. Next, Reimbursement and Incentive Programs for clinical research (ranged from absent to effective), stood out as a problematic area. This is especially concerning for an organization of academic cancer centers, which need to encourage participation in clinical research as part of their operation. Data analysis indicated high levels of concern and variability among perceptions regarding the current state of cancer centers, and a variable but strong desire to improve. This subject area metric needs improvement, but it is not suitable for effective action until the problem and desirable goals can be more clearly defined. By comparison, Clinical Operations (ranged from chaotic to efficient) does not particularly stand out as a subject area metric in dire need of improvement. However, the centers had a strong desire to improve in this area, and more importantly, a very consistent desire to improve. These observations make it a “low-hanging-fruit” option for future action, such that significant improvement might be obtained with relatively lower sustained effort. One viable option given the low variability among desire to improve might be to take lessons from centers that already perceive themselves to be doing well in this subject area metric and transfer these lessons to other centers. 
AACI is also pioneering the inclusion of genetic and biochemical care methods in its academic cancer centers with MDI. This area of research and care methodology is likely to have the largest impact on cancer treatment in the near future as researchers continue to innovate ways to combat a disease that arises primarily from the mutation of the genetic code and the deregulation of the mechanisms of life. Supporting research and implementation of advances in this area will remain a critical healthcare and public health priority for cancer care in the coming years. 
4.1	Recommendations
By surveying physician leadership, PCLI can help keep tabs on how leadership feels their centers are doing, where they feel AACI should go, and where they feel they need support. Annualizing a modified version of this poster exercise could allow PCLI to track improvement over time, analyze response to environmental changes such as major legislation, and provide support to other AACI initiatives. If PCLI steering committee is interested in annualizing this exercise, the following changes would be recommended to improve quality of data collection and analysis. One, link current and future response stickers. By providing response stickers to participants in sets, one red/green pair labelled A and A, or 1 and 1, etc., for each poster, current and future state responses and responses across subject area metrics could be analyzed together while maintaining anonymity. Two, formalize the scale. By switching to a more intuitive 0-100cm scale and displaying the scale quantitatively on the exercise posters, participants could better understand the exact meaning of their response, and have more room on each poster to avoid pileup (i.e. some response stickers overlapping and possibly concealing others). This in turn would increase the reliability of the data collected. Three, encourage consistent participation. By encouraging participants to respond to every poster and encouraging all appropriate attendees to participate, the strength, comparability, and extrapolative ability of the data could be increased. In tandem with attendance records, this would also allow for examination of potential geographical or institutional bias, while still maintaining individual center anonymity.
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